Conjunctival Z-Plasty for Pterygium: Comparison With Conjunctival Autografting

Özdemir, Murat

doi:10.29333/ejgm/82583

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We chose to not administer any kind of injection/placebo prior/after surgery in the control group, since we intended to prevent any inflammatory response, related to the injection itself, that might influence the recurrence rate in this group. Moreover, different excision techniques, even if featured with lower recurrence rate, may be associated with problems such as conjunctival graft edema, graft necrosis, hematoma, Tenon's pyogenic granuloma, corneoscleral dellen, epithelial inclusion cysts, donor site fibrosis (for conjunctival autografting and application of amniotic membrane, as well) [ 14 – 16 ]. In addition, rotational conjunctival autografting cannot be used in cases with large bare scleral area after excision [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence

Nuzzi

Tridico

2017

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To evaluate the efficacy of subconjunctival bevacizumab injections, before and after surgical excision with bare sclera technique, in preventing postoperative pterygium recurrence. Material and Methods 83 eyes of 83 patients affected with primary pterygia underwent surgical excision. 42 eyes received two subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, one week prior surgery and one week after intervention. Recurrence rate was evaluated among the two groups. Moreover, modifications of pterygium size and grade one week after the first injection were evaluated. Results At 6 months after surgery, the recurrence rate was 7.14% in the bevacizumab group and 24.39% in the control group. Significant changes of pterygium size and grade were reported after the first injection. No important complications related to bevacizumab subconjunctival injections were registered. Conclusions The application of subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, before and after surgical pterygium excision, may be useful in preventing lesion recurrence after bare scleral procedures. Furthermore, bevacizumab subconjunctival administration is well tolerated and may represent a safer alternative if compared with other surgical techniques and adjunctive drugs. This trial is retrospectively registered with ISRCTN Registry on 18 April 2017, TRN: ISRCTN11424742.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence

Nuzzi

Tridico

2017

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…We chose not to administer any injection/placebo prior/after surgery in the control group since we intended to prevent any inflammatory response related to the injection that might influence the recurrence rate in this group. Furthermore, different excision techniques, even if featured with lower recurrence rate, may be associated with problems such as conjunctival graft edoema, graft necrosis, hematoma, tenon's pyogenic granuloma, corneoscleral dellen, epithelial inclusion cysts, donor site fibrosis (for conjunctival autografting and application of amniotic membrane, as well) (10) .…”

Section: Discussionmentioning

confidence: 99%

Effect of Subconjunctival Injection of Bevacizumab in Preventing Recurrence of Pterygium before and after Surgical Removal

El-Nahas¹,

Elgharieb²,

Gaballah³

et al. 2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Recurrence, which is indicated by the expansion of fibrovascular tissue past the limbus and onto the cornea, is the main worry in pterygium surgery. Several techniques have been put forth to slow the pace of recurrence. Pterygium recurrences typically occur within the first three months following surgery. Objective: To evaluate the efficacy of a protocol based on applying two 2.5 mg/ml bevacizumab injections, before and after surgery, as adjuvant therapy of surgical pterygium excision to assess its role in preventing the recurrence of pterygium. Patients and Methods: A randomized control study was conducted on 84 patients. Complete ophthalmic examinations were performed on all patients, including the following: history, visual acuity, slit lamp examination, intraocular pressure (IOP) measurement, fundus examination, and Refraction by Auto refractometer. Results: The recurrence rate was significantly lower in the group that underwent pre-and postoperative bevacizumab injection. Moreover, we observed improvements in dimensions and vascularization of pterygium one week after the first subconjunctival injection. In our study, there were some postoperative complications; most of them in the pretreated group were related to pterygium surgery, such as subconjunctival hemorrhage, photophobia, and conjunctival injection. All of these complications occurred in both groups, but with the use of bevacizumab the field was less vascular, and the subconjunctival hemorrhage was less remarkable in the pretreated group than in the control group. Conclusion: Dimensions and vascularization of pterygium significantly decreased one week after the first subconjunctival bevacizumab injection. The recurrence rate was significantly decreased in the group that underwent pre-and postoperative bevacizumab injection.

show abstract

“…We chose to not administer any kind of injection/placebo prior/after surgery in the control group, since we intended to prevent any inflammatory response, related to the injection itself, that might influence the recurrence rate in this group. Moreover, different excision techniques, even if featured with lower recurrence rate, may be associated with problems such as conjunctival graft edema, graft necrosis, hematoma, Tenon's pyogenic granuloma, corneoscleral dellen, epithelial inclusion cysts, donor site fibrosis (for conjunctival autografting and application of amniotic membrane, as well) [14][15][16]. In addition, rotational conjunctival autografting cannot be used in cases with large bare scleral area after excision [17].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of subconjunctival bevacizumab injections before and after surgical excision in preventing pterygium recurrence

Nuzzi¹

2017

http://isrctn.com/

View full text Add to dashboard Cite

Purpose. To evaluate the efficacy of subconjunctival bevacizumab injections, before and after surgical excision with bare sclera technique, in preventing postoperative pterygium recurrence. Material and Methods. 83 eyes of 83 patients affected with primary pterygia underwent surgical excision. 42 eyes received two subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, one week prior surgery and one week after intervention. Recurrence rate was evaluated among the two groups. Moreover, modifications of pterygium size and grade one week after the first injection were evaluated. Results. At 6 months after surgery, the recurrence rate was 7.14% in the bevacizumab group and 24.39% in the control group. Significant changes of pterygium size and grade were reported after the first injection. No important complications related to bevacizumab subconjunctival injections were registered. Conclusions. The application of subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, before and after surgical pterygium excision, may be useful in preventing lesion recurrence after bare scleral procedures. Furthermore, bevacizumab subconjunctival administration is well tolerated and may represent a safer alternative if compared with other surgical techniques and adjunctive drugs. This trial is retrospectively registered with ISRCTN Registry on 18 April 2017, TRN: ISRCTN11424742.

show abstract

Conjunctival Z-Plasty for Pterygium: Comparison With Conjunctival Autografting

Cited by 5 publications

References 29 publications

Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence

Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence

Effect of Subconjunctival Injection of Bevacizumab in Preventing Recurrence of Pterygium before and after Surgical Removal

Efficacy of subconjunctival bevacizumab injections before and after surgical excision in preventing pterygium recurrence

Contact Info

Product

Resources

About